Ammonia
[Ammonia ]
EPTIS factsheet 142631 | Last revision 2024-05-21 | URL: https://www.eptis.bam.de/pts142631 https://www.eptis.bam.de/pts142631
| PT provider | |||||||
| PT provider | Weqas Weqas | ||||||
| Based in | United Kingdom | ||||||
| Language(s) | |||||||
| Remarks | The Ammonia programme is available as part of a comprehensive suite of programmes to assess and monitor the performance of the Clinical Biochemistry laboratory’s repertoire of both core and esoteric tests used for the diagnosis and monitoring of disease. Ammonia is analysed as part of the diagnostic investigation of the unconscious patient, to support the diagnosis of Reye’s syndrome and hepatic encephalopathy and in identification and management of a urea cycle defect. A range of Ammonia samples are distributed covering both normal and pathological levels including those seen in urea cycle defects. The material is liquid human serum, this matrix is commutable and compatible with all enzymatic methods assayed on laboratory analysers, dry slide chemistry analysers and Point of Care devices (POCT). Three aqueous samples are distributed monthly, with a minimum of 36 samples distributed over the year covering a wide clinically relevant range. The samples consist of a panel of 6 linearly related samples distributed on a number of occasions over that period which are used to assess both laboratory and method performance, including linearity, bias, within and between batch imprecision. Key Features: - Ammonia levels covering relevant clinical and analytical range. - Samples suitable for Laboratory and POCT devices. - Commutable Liquid human serum. - Programme assesses laboratory and method performance, including bias, within and between batch imprecision and linearity. - Analytical Performance Specification based on Milan Model 3. For more information: https://www.weqas.com/services/eqa/ammonia/ or contact@weqas.com | ||||||
| Keywords | |||||||
| Product groups |
Health care / medical devices
|
||||||
| Testing fields |
Medical analysis
|
||||||
| Technical details | |||||||
|
|||||||
| Aims of the PT scheme | |||||||
| Target group of participants | Samples suitable for Laboratory and POCT devices. | ||||||
| Linked to specific legislation / standards | Accreditation by UKAS on the basis of ISO/IEC 17025, 17043 and 15195 | ||||||
| Additional, subsidiary aims | validation of testing methods | ||||||
| Number of participants | |||||||
| Accredited or otherwise reviewed by a 3rd party |
Accredited by UKAS on the basis of ISO/IEC 17043 |
||||||
| Operation is commissioned / requested by | |||||||
| Fees and frequency | |||||||
| Participation fee | https://www.weqas.com/participantzone/subscription-charges/ | ||||||
| Regularly operated | Yes (Frequency: Monthly. Samples: 3 x 0.5mL.) | ||||||
| Year of first operation | 2002 | ||||||
| Contact details of the PT provider | |||||||
| Provider | Contact person | ||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Phone: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Phone: 44 (0) 29218 32884 Fax: Email: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
||||||
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.